Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN II 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN 20 versus LIPOSYN II 20.
LIPOSYN 20% vs LIPOSYN II 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn 20% is an intravenous fat emulsion providing essential fatty acids (linoleic and linolenic acids) and triglycerides. It serves as a caloric source and prevents essential fatty acid deficiency by supplying substrate for energy metabolism and cell membrane synthesis.
Lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy or stored.
Intravenous infusion: 1-2 g/kg/day (as soybean oil) initially, up to 2.5 g/kg/day, not to exceed 50% of total caloric intake; infusion rate not to exceed 0.1 g/kg/hour for first 30 minutes; if no adverse reactions, may increase to 0.2 g/kg/hour.
Intravenous fat emulsion; 20% formulation: Initial rate 1 mL/min for 15-30 minutes, then increase to 2 mL/min if tolerated. Max infusion rate: 100 mL/hour. Total daily dose: 1-2 g/kg (5-10 mL/kg) to provide up to 60% of nonprotein calories.
None Documented
None Documented
Triglyceride clearance half-life approximately 30-60 minutes; depends on lipase activity and clinical status.
Terminal elimination half-life of triglycerides is approximately 30 minutes for the fast phase and 12-24 hours for the slow phase, reflecting clearance from plasma and tissue distribution.
Lipids are metabolized; <10% excreted renally as free fatty acids; biliary/fecal excretion minimal.
Intravenous lipid emulsions are metabolized by lipoprotein lipase and eliminated as free fatty acids; less than 1% excreted unchanged in urine, negligible biliary/fecal excretion.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion